Core Viewpoint - Tonghua Dongbao (600867) is currently in the preclinical research phase for its insulin weekly formulation, with future research progress to be disclosed according to relevant regulations and requirements [1] Group 1 - The company has a strategic focus on developing insulin weekly formulations [1] - The research is currently at the preclinical stage, indicating ongoing development efforts [1] - The company will provide updates on research progress through regular reports and announcements [1]

Core Viewpoint - The company is currently engaged in the development of insulin depot formulations and is in the preclinical research stage for its fourth-generation insulin products [1] Group 1 - The company has received inquiries from investors regarding its plans for fourth-generation insulin depot formulations [1] - The company confirmed that it has relevant research and development activities in insulin depot formulations [1] - Future research and development progress will be disclosed in accordance with relevant regulations and requirements [1]